MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock and...
$38,234K
Net cash provided by
financing activities
$37,532K
Canceled cashflow
$702K
Net increase in
cash, cash...
$18,745K
Canceled cashflow
$18,787K
Offering costs for common
stock and warrants...
$686K
Payment of employee tax
obligations related to...
$16K
Change in fair value of
derivative liabilities
-$12,541K
Stock-based compensation
expense
$581K
Accretion of debt discount
and amortization of...
$440K
Operating lease
right-of-use assets
$82K
Depreciation
$75K
Inventory
-$47K
Accounts receivable
-$17K
Payable-in-kind interest on
credit agreement
$1K
Net cash used in
operating activities
-$18,787K
Canceled cashflow
$13,784K
Net loss
-$30,911K
Accounts payable,
accrued expenses, due to...
-$1,084K
Prepaid expenses, other
current assets and other...
$480K
Operating lease
liabilities
-$96K
Back
Back
Cash Flow
source: myfinsight.com
BioXcel Therapeutics, Inc. (BTAI)
BioXcel Therapeutics, Inc. (BTAI)